RGLS NASDAQ
Regulus Therapeutics Inc.
1W: -0.6%
1M: +3.2%
3M: +532.6%
1Y: +298.1%
3Y: +191.4%
5Y: -2.9%
$8.16
Last traded 2025-06-26 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$565.0M
52W Range0.8301-8.345
Volume8,756,394
Avg Volume2,475,632
Beta0.37
Dividend—
Analyst Ratings
Company Info
CEOJoseph P. Hagan
Employees34
SectorHealthcare
IndustryBiotechnology
IPO Date2012-10-09
Websiteregulusrx.com
4224 Campus Point Court
San Diego, CA 92121
US
San Diego, CA 92121
US
858 202 6300
About Regulus Therapeutics Inc.
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| RASTETTER WILLIAM H | U-Tender | 44,264 | — | 2025-06-25 |
| RASTETTER WILLIAM H | D-Return | 30,000 | $1.45 | 2025-06-25 |
| RASTETTER WILLIAM H | D-Return | 15,000 | $1.36 | 2025-06-25 |
| RASTETTER WILLIAM H | D-Return | 60,000 | $2.01 | 2025-06-25 |
| RASTETTER WILLIAM H | D-Return | 2,325 | $8.80 | 2025-06-25 |